Markus Alexander Zeitlinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3292564/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology, 2003, 30, 285-291.	0.6	123
2	Target site penetration of fosfomycin in critically ill patients. Journal of Antimicrobial Chemotherapy, 2003, 51, 1247-1252.	3.0	114
3	Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. Journal of Antimicrobial Chemotherapy, 2004, 53, 848-852.	3.0	107
4	A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (<i>R</i>)- ¹¹ C-Verapamil and PET. Journal of Nuclear Medicine, 2009, 50, 1954-1961.	5.0	99
5	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica, 2012, 97, 1431-1438.	3.5	96
6	Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infectious Diseases, The, 2013, 13, 680-689.	9.1	84
7	Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses. Antimicrobial Agents and Chemotherapy, 2005, 49, 2367-2371.	3.2	78
8	Approaching Complete Inhibition of P-Glycoprotein at the Human Blood–Brain Barrier: An (<i>R</i>)-[¹¹ C]Verapamil PET Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 743-746.	4.3	74
9	Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. European Journal of Clinical Pharmacology, 2009, 65, 941-946.	1.9	65
10	Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses. Antimicrobial Agents and Chemotherapy, 2002, 46, 3724-3730.	3.2	63
11	Pharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients. Antimicrobial Agents and Chemotherapy, 2005, 49, 650-655.	3.2	57
12	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs inÂHumans. Gastroenterology, 2017, 152, 980-982.e3.	1.3	57
13	Protein Binding of Antimicrobials: Methods for Quantification and for Investigation of its Impact on Bacterial Killing. AAPS Journal, 2009, 11, 1-12.	4.4	56
14	[18 F]Ciprofloxacin, a New Positron Emission Tomography Tracer for Noninvasive Assessment of the Tissue Distribution and Pharmacokinetics of Ciprofloxacin in Humans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3850-3857.	3.2	54
15	Lung microdialysis—A powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS Journal, 2005, 7, E600-E608.	4.4	50
16	A Cell Culture (Vero)–Derived H5N1 Wholeâ€Virus Vaccine Induces Crossâ€Reactive Memory Responses. Journal of Infectious Diseases, 2009, 200, 1113-1118.	4.0	48
17	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically III Patients. Clinical Pharmacokinetics, 2017, 56, 617-633.	3.5	47
18	Interaction of ¹¹ C-Tariquidar and ¹¹ C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2013, 54, 1181-1187.	5.0	45

#	Article	IF	CITATIONS
19	Plasma protein binding of fluoroquinolones affects antimicrobial activity. Journal of Antimicrobial Chemotherapy, 2008, 61, 561-567.	3.0	44
20	Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Detection Tests Using Oral, Anterior Nasal, and Nasopharyngeal Swabs: a Diagnostic Accuracy Study. Microbiology Spectrum, 2022, 10, e0202921.	3.0	44
21	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 2018, 104, 139-147.	4.7	43
22	Tissue pharmacokinetics of levofloxacin in human soft tissue infections. British Journal of Clinical Pharmacology, 2004, 57, 563-568.	2.4	42
23	Pharmacokinetics of Single- and Multiple-Dose Oral Clarithromycin in Soft Tissues Determined by Microdialysis. Antimicrobial Agents and Chemotherapy, 2007, 51, 3185-3189.	3.2	42
24	Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Research in Microbiology, 2011, 162, 249-252.	2.1	41
25	Neutralization of Antimicrobial Substances in New BacT/Alert FA and FN Plus Blood Culture Bottles. Journal of Clinical Microbiology, 2013, 51, 1534-1540.	3.9	41
26	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate ¹¹ C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	5.0	38
27	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.1	37
28	The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Medicine, 2008, 34, 1827-1834.	8.2	36
29	A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato. Vaccine Journal, 2014, 21, 1490-1499.	3.1	36
30	Internal Mammary Artery Harvesting Influences Antibiotic Penetration Into Presternal Tissue. Annals of Thoracic Surgery, 2013, 95, 1323-1330.	1.3	35
31	Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. Journal of Nuclear Medicine, 2005, 46, 1835-41.	5.0	35
32	Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood–Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 510-515.	4.3	34
33	Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Antimicrobial Agents and Chemotherapy, 2016, 60, 3617-3625.	3.2	34
34	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death and Disease, 2017, 8, e3135-e3135.	6.3	34
35	Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. Journal of Antimicrobial Chemotherapy, 2006, 58, 367-371.	3.0	32
36	A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil. Clinical Pharmacokinetics, 2011, 50, 111-120.	3.5	31

#	Article	IF	CITATIONS
37	Absolute Oral Bioavailability and Metabolic Turnover of β-Sitosterol in Healthy Subjects. Drug Metabolism and Disposition, 2012, 40, 2026-2030.	3.3	31
38	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	6.4	30
39	Ketolides – The Modern Relatives of Macrolides. Clinical Pharmacokinetics, 2009, 48, 23-38.	3.5	29
40	Development of a Population Pharmacokinetic Model Characterizing the Tissue Distribution of Azithromycin in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 6675-6684.	3.2	29
41	Effect of Pâ€g ycoprotein inhibition at the blood–brain barrier on brain distribution of (<i>R</i>)â€{ ¹¹ C]verapamil in elderly <i>vs.</i> young subjects. British Journal of Clinical Pharmacology, 2017, 83, 1991-1999.	2.4	28
42	Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine, 2010, 29, 166-173.	3.8	26
43	Platelet activation at the onset of human endotoxemia is undetectable <i>in vivo</i> . Platelets, 2016, 27, 479-483.	2.3	26
44	Pharmacokinetics of Telithromycin in Plasma and Soft Tissues after Single-Dose Administration to Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2004, 48, 4650-4653.	3.2	25
45	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	5.0	25
46	Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 383-390.	0.6	25
47	Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming. Vaccine, 2012, 30, 6127-6135.	3.8	23
48	Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with (<i>R</i>)â€ ¹¹ C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	5.0	23
49	Pharmacokinetics of Intraperitoneal and Intravenous Fosfomycin in Automated Peritoneal Dialysis Patients without Peritonitis. Antimicrobial Agents and Chemotherapy, 2012, 56, 3992-3995.	3.2	21
50	Development of a high-performance liquid chromatography method for the determination of caspofungin with amperometric detection and its application to in vitro microdialysis experiments. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 142-146.	2.3	20
51	Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. Journal of Antimicrobial Chemotherapy, 2006, 59, 219-223.	3.0	19
52	Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. Journal of Antimicrobial Chemotherapy, 2009, 64, 821-823.	3.0	19
53	Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. Journal of Pharmaceutical and Biomedical Analysis, 2019, 163, 34-38.	2.8	19
54	Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 599-606.	1.6	18

#	Article	IF	CITATIONS
55	Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides. Clinical Pharmacokinetics, 2018, 57, 797-816.	3.5	17
56	Effect of Rifampicin on the Distribution of [¹¹ C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	4.6	17
57	Penetration of Doripenem into Skeletal Muscle and Subcutaneous Adipose Tissue in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2012, 56, 532-535.	3.2	16
58	Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans. AAPS Journal, 2013, 15, 95-103.	4.4	16
59	Feasibility of microdialysis for determination of protein binding and target site pharmacokinetics of colistin in vivo. Journal of Clinical Pharmacology, 2015, 55, 431-437.	2.0	16
60	Cerebral and Peripheral Metabolism to Predict Successful Reperfusion After Cardiac Arrest in Rats: A Microdialysis Study. Neurocritical Care, 2016, 24, 283-293.	2.4	16
61	Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia. Antimicrobial Agents and Chemotherapy, 2007, 51, 1879-1881.	3.2	15
62	Intra-Cystic Drug Concentration of Albendazole Sulphoxide in Patients with Echinococcus granulosus Cysts. American Journal of Tropical Medicine and Hygiene, 2009, 81, 712-713.	1.4	15
63	Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine, 2012, 30, 4543-4551.	3.8	15
64	Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. International Journal of Antimicrobial Agents, 2012, 39, 343-345.	2.5	15
65	Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. Drugs, 2018, 78, 799-808.	10.9	15
66	Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model. International Journal of Antimicrobial Agents, 2003, 22, 574-578.	2.5	14
67	An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2016, 60, 2790-2797.	3.2	14
68	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. AAPS Journal, 2019, 21, 61.	4.4	14
69	Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro. Journal of Antimicrobial Chemotherapy, 2008, 62, 1057-1060.	3.0	13
70	Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection. Journal of Clinical Pharmacology, 2014, 54, 1058-1062.	2.0	13
71	Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. European Journal of Cardio-thoracic Surgery, 2015, 48, 758-764.	1.4	13
72	Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. European Journal of Clinical Pharmacology, 2017, 73, 1609-1613.	1.9	13

#	Article	IF	CITATIONS
73	Microdialysis Assessment of Cerebral Perfusion during Cardiac Arrest, Extracorporeal Life Support and Cardiopulmonary Resuscitation in Rats – A Pilot Trial. PLoS ONE, 2016, 11, e0155303.	2.5	13
74	Clinical Applications of Levofloxacin for Severe Infections. Chemotherapy, 2004, 50, 16-21.	1.6	12
75	Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. European Journal of Clinical Pharmacology, 2015, 71, 1359-1364.	1.9	12
76	Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro. Pharmacology, 2016, 97, 233-244.	2.2	12
77	Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3179-3184.	3.0	12
78	High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. European Journal of Pharmaceutical Sciences, 2019, 131, 218-229.	4.0	12
79	Circulating Tuberculostearic Acid in Tuberculosis Patients. Scandinavian Journal of Infectious Diseases, 2003, 35, 790-793.	1.5	11
80	Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically III and Immunocompromised Patients. Vaccine Journal, 2014, 21, 867-876.	3.1	11
81	Whole-Body Distribution and Radiation Dosimetry of ¹¹ C-Elacridar and ¹¹ C-Tariquidar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11
82	Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2016, 55, 47-77.	3.5	11
83	Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
84	Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. Thrombosis and Haemostasis, 2017, 117, 1714-1721.	3.4	11
85	The European Association for Clinical Pharmacology and Therapeutics—25Âyears' young and going strong. European Journal of Clinical Pharmacology, 2019, 75, 743-750.	1.9	11
86	A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. Journal of Dermatological Treatment, 2015, 26, 367-372.	2.2	10
87	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Molecular Cancer, 2022, 21, 7.	19.2	10
88	Target site pharmacokinetics of doxycycline for rosacea in healthy volunteers is independent of the food effect. British Journal of Clinical Pharmacology, 2018, 84, 2625-2633.	2.4	9
89	Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	9
90	Influence of the Washing Buffer Composition on the Sensitivity of an Enzymeâ€Linked Immunosorbent Assay Using Mycobacterial Glycolipids as Capture Antigens. Journal of Immunoassay and Immunochemistry, 2005, 26, 179-188.	1.1	8

#	Article	IF	CITATIONS
91	Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid. Research in Microbiology, 2012, 163, 157-160.	2.1	8
92	Influence of Different Peritoneal Dialysis Fluids on theIn VitroActivity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin againstEscherichia Coli. Peritoneal Dialysis International, 2016, 36, 662-668.	2.3	8
93	Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers. Scientific Reports, 2017, 7, 9644.	3.3	8
94	Assessing Pharmacokinetics of Different Doses of Fosfomycin in Laboratory Rats Enables Adequate Exposure for Pharmacodynamic Models. Pharmacology, 2014, 93, 65-68.	2.2	7
95	Lack of dermal penetration of topically applied gentamicin as pharmacokinetic evidence indicating insufficient efficacy. Journal of Antimicrobial Chemotherapy, 2018, 73, 2823-2829.	3.0	7
96	Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 485-495.	2.9	7
97	In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid. Infection, 2019, 47, 565-570.	4.7	7
98	Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1091-1098.	2.9	6
99	Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Scientific Reports, 2019, 9, 6512.	3.3	6
100	Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents. Clinical Pharmacokinetics, 2020, 59, 827-847.	3.5	6
101	Comparison of non-invasive Staphylococcus aureus sampling methods on lesional skin in patients with atopic dermatitis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 245-252.	2.9	6
102	A Randomised, Two-Period, Cross-Over, Open-Label Study to Evaluate the Pharmacokinetic Profiles of Single Doses of Two Different Flurbiprofen 8.75-mg Lozenges in Healthy Volunteers. Pharmacology, 2012, 89, 188-191.	2.2	5
103	Compatibility of Meropenem with Different Commercial Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2017, 37, 51-55.	2.3	5
104	A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1097-1106.	3.0	5
105	Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clinical Pharmacokinetics, 2022, , 1.	3.5	5
106	Methods to measure target site penetration of antibiotics in critically ill patients. Current Clinical Pharmacology, 2013, 8, 46-58.	0.6	5
107	Good Penetration of Moxifloxacin into Human Abscesses. Pharmacology, 2012, 90, 146-150.	2.2	4
108	Assessing the influence of diurnal variations and selective Xa inhibition on whole blood aggregometry. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 531-536.	1.2	4

#	Article	IF	CITATIONS
109	An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 390-395.	1.4	4
110	A Prediction Method for P-glycoprotein–Mediated Drug–Drug Interactions at the Human Blood–Brain Barrier From Blood Concentration–Time Profiles, Validated With PET Data. Journal of Pharmaceutical Sciences, 2017, 106, 2780-2786.	3.3	4
111	Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Expert Review of Clinical Pharmacology, 2021, 14, 777-791.	3.1	4
112	Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	4
113	Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacology, 2016, 98, 93-98.	2.2	3
114	Compatibility of linezolid with commercial peritoneal dialysis solutions. American Journal of Health-System Pharmacy, 2018, 75, 1467-1477.	1.0	3
115	Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2681-2689.	3.0	3
116	Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an <i>In Vivo</i> Microdialysis Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0067921.	3.2	3
117	Removal of fractured endodontic instruments using an Nd:YAG laser. Quintessence International, 2014, 45, 569-75.	0.4	3
118	High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	3
119	A combined accelerator mass spectrometry/positron emission tomography microdose study to assess the plasma and brain tissue pharmacokinetics of 11C- and 14C-labelled verapamil in healthy volunteers. BMC Pharmacology, 2008, 8, .	0.4	2
120	Comment on: Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. Journal of Antimicrobial Chemotherapy, 2018, 73, 2587-2588.	3.0	2
121	Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients. Current Clinical Pharmacology, 2013, 8, 46-58.	0.6	1
122	Extended infusion—putting the benefit into context. Lancet Infectious Diseases, The, 2018, 18, 380-381.	9.1	1
123	"latrogenicity cascade": Doing harm by treating harm?. Wiener Medizinische Wochenschrift, 2009, 159, 53-57.	1.1	Ο
124	Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus. European Journal of Clinical Pharmacology, 2012, 68, 1419-1423.	1.9	0
125	Reply. Annals of Thoracic Surgery, 2013, 96, 1528-1529.	1.3	0
126	Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients― Clinical Pharmacokinetics, 2019, 58, 981-982.	3.5	0